Global Gastroenteritis Testing Market, By Disease Strains (Bacterial Strains, Viral Strains, and Parasitic Strains), Product Type (Reagent Kits and Sequencing Kits and Equipment), Testing Methods (Immunoassay Testing, Conventional Testing, and Molecular Diagnostic Testing), End-User (Hospitals, Clinics/Medical Centers, Research Institutes, and Diagnostic Laboratories) – Industry Trends and Forecast to 2031.
Gastroenteritis Testing Market Analysis and Size
The global gastroenteritis testing market is driven by the increasing prevalence of gastrointestinal infections worldwide, fueled primarily by viral, bacterial, and parasitic pathogens. This market growth is further propelled by rising public health awareness and initiatives aimed at early diagnosis and effective management of gastroenteritis. Diagnostic technologies such as molecular diagnostics (PCR), antigen detection assays, and culture tests play a crucial role in accurately identifying the causative agents of gastroenteritis, facilitating prompt treatment and reducing transmission rates. Moreover, advancements in diagnostic techniques and the integration of automated platforms enhance testing efficiency and accuracy, supporting healthcare providers in delivering timely and precise diagnostic results. Geographically, North America leads the market due to robust healthcare infrastructure, high awareness levels, and significant investments in healthcare technologies.
Global gastroenteritis testing market size was valued at USD 3.99 billion in 2023 and is projected to reach USD 5.90 billion by 2031, with a CAGR of 5.0% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Strains (Bacterial Strains, Viral Strains, and Parasitic Strains), Product Type (Reagent Kits and Sequencing Kits and Equipment), Testing Methods (Immunoassay Testing, Conventional Testing, and Molecular Diagnostic Testing), End-User (Hospitals, Clinics/Medical Centers, Research Institutes, and Diagnostic Laboratories)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America
|
|
Market Players Covered
|
BD (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Hainan Poly Co. Ltd (China), WOCKHARDT (India)
|
|
Market Opportunities
|
|
Market Definition
Gastroenteritis testing refers to diagnostic procedures aimed at identifying and confirming the presence of gastroenteritis, an inflammation of the gastrointestinal tract typically caused by viral, bacterial, or parasitic infections. These tests may involve various methods such as stool analysis, molecular diagnostics (PCR), antigen detection assays, and culture tests to detect pathogens responsible for gastroenteritis symptoms such as diarrhea, vomiting, abdominal pain, and fever.
Gastroenteritis Testing Market Dynamics
Drivers
- Increasing Prevalence of Gastrointestinal Infections
The rising incidence of viral, bacterial, and parasitic infections leading to gastroenteritis causes symptoms such as diarrhea, vomiting, abdominal pain, and fever, necessitating accurate and timely diagnosis to guide appropriate treatment. For instance, according to the National Library of Medicine, the U.S. experiences over 350 million cases of acute gastroenteritis each year, with food-borne bacteria responsible for approximately 48 million of these cases. The increasing awareness among healthcare providers and the general public about the potential severity and transmission of gastrointestinal infections further underscores the importance of diagnostic testing in managing and containing outbreaks. As healthcare systems worldwide prioritize early detection and containment of infectious diseases, the demand for efficient gastroenteritis tests continues to grow and is a significant driver for the demand for diagnostic testing globally.
- Advancements in Diagnostic Technologies
Technological advancements in gastroenteritis testing, such as PCR (Polymerase Chain Reaction), antigen detection assays, and automated platforms, play a pivotal role in enhancing the accuracy and efficiency of diagnostic procedures. PCR allows for rapid and specific detection of pathogens, while antigen detection assays offer quick results suitable for point-of-care testing. Automated platforms streamline laboratory workflows, reducing turnaround times and improving diagnostic capabilities. These advancements not only enable healthcare providers to diagnose gastroenteritis more effectively but also contribute to better patient outcomes through prompt initiation of targeted treatments and infection control measures, driving the market growth.
Opportunities
- Technological Innovations and Product Development
Novel assays incorporating advanced molecular techniques and biomarkers enhance diagnostic sensitivity and specificity, facilitating early and accurate detection of gastrointestinal pathogens. Point-of-care testing devices offer rapid results outside traditional laboratory settings, improving access to diagnostics in remote or resource-limited areas. Multiplex testing platforms enable simultaneous detection of multiple pathogens, optimizing diagnostic efficiency and reducing testing costs. The gastroenteritis testing market presents opportunities for developing novel diagnostic assays, point-of-care testing devices, and multiplex testing platforms.
- Focus on Preventive Healthcare
Preventive healthcare initiatives educate populations about the importance of hygiene, vaccination, and early symptom recognition, reducing the incidence and severity of gastrointestinal infections. Early detection through screening programs and routine diagnostic testing allows for timely intervention and treatment, mitigating disease spread and complications. Healthcare providers are increasingly integrating preventive healthcare measures into primary care settings, promoting proactive management of gastrointestinal health and driving the adoption of diagnostic testing for gastroenteritis. The emphasis on preventive healthcare strategies and public health campaigns is boosting the demand for early screening and gastroenteritis tests.
Restraints/Challenges
- High Cost of Diagnostic Tests
Advanced molecular diagnostics and automated platforms require substantial initial investment in equipment, reagents, and trained personnel, increasing overall healthcare expenditure. This cost-intensive nature limits the affordability and availability of diagnostic testing in underserved populations, hindering timely diagnosis and treatment. The high cost associated with advanced gastroenteritis diagnostic tests poses a significant barrier to accessibility, particularly in resource-constrained settings.
- Challenges in Pathogen Detection
Viruses, bacteria, and parasites exhibit diverse genetic profiles and antigenic variability, requiring robust diagnostic assays capable of detecting multiple pathogens simultaneously. The need for accurate pathogen identification is paramount in guiding appropriate treatment decisions and infection control measures. In addition, the emergence of new pathogens and antimicrobial resistance further complicates diagnostic efforts, necessitating continuous research and development in diagnostic technologies. Detecting the wide variability of pathogens responsible for gastroenteritis poses challenges to diagnostic accuracy and efficiency.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In June 2022, Prenetics Group Limited, in collaboration with New Horizon Health, introduced ColoClear by Circle (ColoClear), an innovative, non-invasive at-home screening test for early detection of colorectal cancer. This novel screening test utilizes advanced technology to identify multiple DNA biomarkers and blood cells in human stool
- In December 2022, Shineco, Inc. obtained approval from the United States Food and Drug Administration (FDA) and a patent from the United States Patent and Trademark Office (US PTO) for its in-situ fecal specimen sampling device designed for stool sample collection. The product features a fingertip swab similar to a massager, a collection tube, and a lid equipped with a unidirectional sampling inlet
Gastroenteritis Testing Market Scope
The market is segmented on the basis of disease strains, product type, testing methods, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Strains
- Bacterial Strains
- Viral Strains
- Parasitic Strains
Product Type
- Reagent Kits
- Sequencing Kits and Equipment
Testing Methods
- Immunoassay Testing
- Conventional Testing
- Molecular Diagnostic Testing
End-User
- Hospitals
- Clinics/Medical Centers
- Research Institutes
- Diagnostic Laboratories
Gastroenteritis Testing Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, disease strains, product type, testing methods, and end-user as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America is expected to dominate the market due to heightened public awareness and an increasing demand for advanced diagnostic testing products. The region benefits from a robust healthcare infrastructure and proactive healthcare initiatives, which contribute to early disease detection and management.
Asia-Pacific is expected to witness significant growth during the forecast period due to rapid technological advancements in diagnostic tools and healthcare systems. The region's expanding healthcare infrastructure, coupled with rising healthcare expenditure and awareness, supports the adoption of advanced gastroenteritis testing methods.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Gastroenteritis Testing Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- BD (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Hainan Poly Co. Ltd (China)
- WOCKHARDT (India)
SKU-